Abpro Holdings, Inc. income statement ABPO

Annual Quarterly

It recorded a net loss of $2.9 million. Diluted earnings per share were -$1.30.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
Revenue
—
0
Research and development
1
-66.8%
3
Selling, general and administrative
7
+4.8%
7
Operating income
-8
+14.8%
-10
+15.5%
Pretax income
—
-7
+38.2%
Net income
-3
+60.0%
-7
Basic EPS
-1.30
+94.2%
-22.31
Diluted EPS
-1.30
+94.2%
-22.31
Weighted average shares, basic
2
+186.1%
1
Weighted average shares, diluted
2
+186.1%
1
Other measures
Depreciation and amortization
0
-71.6%
0
EBITDA
-8
+14.4%
-10
Interest coverage
-7.49x
-25.64x
Margins
Operating margin
—
-5,421.31%
Pretax margin
—
-3,951.91%
Profit margin
—
-3,951.91%
EBITDA margin
—
-5,380.87%
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
ABPO (OTC), ABPWW (OTC)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
New York, NY
SEC filer status
Non-accelerated filer, Smaller reporting company, Emerging growth company
SEC CIK
1893219
Former names
Atlantic Coastal Acquisition Corp. II (until Nov 12, 2024)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.